Rituximab in lymphocyte predominance Hodgkin's disease: a case series.

Published

Journal Article

Rituximab in combination with chlorambucil or radiation therapy may be an effective and less-toxic therapeutic alternative for patients with lymphocyte predominance Hodgkin's disease (LPHD). We treated 6 patients with LPHD with weekly rituximab at 375 mg/m2 for 4 weeks, followed by either radiation therapy or chlorambucil. Four patients had previously untreated disease and 2 had relapsed LPHD. All patients had no evidence of disease progression at a median follow-up time of 12.5 months after receiving rituximab therapy (range, 6-39 months) and a median follow-up time of 6.5 months after completion of chlorambucil or radiation therapy (range, 3-25 months). Further follow-up is warranted to evaluate response duration and late toxicity of this novel treatment strategy

Full Text

Duke Authors

Cited Authors

  • Ibom, VK; Prosnitz, RG; Gong, JZ; Moore, JO; DeCastro, CM; Prosnitz, LR; Rizzieri, DA; Gockerman, JP

Published Date

  • September 2003

Published In

Volume / Issue

  • 4 / 2

Start / End Page

  • 115 - 118

PubMed ID

  • 14556684

Pubmed Central ID

  • 14556684

International Standard Serial Number (ISSN)

  • 1526-9655

Language

  • eng

Conference Location

  • United States